Y-Intercept (HK)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Y-Intercept (HK)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.62M	Sell	78,354 -140,000	-64%	-$3.48M	0.05%	554
2026 Q1	$4.57M	Buy	+218,354	New	+$4.92M	0.09%	347
2025 Q4	–	Sell	-67,834	Closed	-$2.04M	–	1920
2025 Q3	$2.04M	Buy	67,834 +16,096	+31%	+$483K	0.05%	592
2025 Q2	$1.88M	Buy	51,738 +27,138	+110%	+$978K	0.05%	636
2025 Q1	$891K	Sell	24,600 -2,095	-8%	-$87.2K	0.06%	447
2024 Q4	$1.12M	Buy	26,695 +7,544	+39%	+$374K	0.07%	383
2024 Q3	$1.06M	Buy	19,151 +12,617	+193%	+$643K	0.07%	426
2024 Q2	$269K	Sell	6,534 -4,590	-41%	-$196K	0.01%	1066
2024 Q1	$519K	Buy	+11,124	New	+$525K	0.04%	694
2023 Q4	–	Sell	-15,442	Closed	-$551K	–	1581
2023 Q3	$551K	Buy	+15,442	New	+$612K	0.05%	531
2022 Q1	–	Sell	-2,998	Closed	-$252K	–	908
2021 Q4	$252K	Buy	+2,998	New	+$244K	0.06%	448
2021 Q3	–	Sell	-5,294	Closed	-$505K	–	861
2021 Q2	$505K	Buy	5,294 +943	+22%	+$98.2K	0.13%	268
2021 Q1	$488K	Buy	4,351 +1,182	+37%	+$161K	0.13%	263
2020 Q4	$458K	Buy	+3,169	New	+$376K	0.19%	181

Other funds holding RARE

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

SOAM

SBI Okasan Asset Management Tokyo, Japan $3.04B AUM

Y-Intercept (HK)'s RARE Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Ultragenyx Pharmaceutical (RARE) stake by 64% in Q2 2026, selling an estimated $3.48M and leaving 78,354 shares worth $2.62M. The position accounts for 0.05% of the portfolio, ranked #554.

Y-Intercept (HK) first reported a position in RARE in Q4 2020 and has held it in 14 quarters since. The position peaked at $4.57M in Q1 2026. 30 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Y-Intercept (HK) held 78,354 shares of Ultragenyx Pharmaceutical worth $2.62M as of Q2 2026.
Y-Intercept (HK) sold 140,000 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $3.48M.
Ultragenyx Pharmaceutical made up 0.05% of Y-Intercept (HK)'s portfolio in Q2 2026, its #554 holding.
Y-Intercept (HK) first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and has held it in 14 quarters since.
Y-Intercept (HK)'s Ultragenyx Pharmaceutical position peaked at $4.57M in Q1 2026.
30 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.